MG53 is an important membrane repair protein and partially protects bone marrow multipotent adult progenitor cells (MAPCs) against oxidized low-density lipoprotein 
| INTRODUC TI ON
Bone marrow stem cells (BMSCs) are important sources for cellbased therapy that remains a viable and attractive option for tissue repair and regeneration. [1] [2] [3] [4] [5] However, one of the major challenges for cell-based therapy with stem cells is the poor in vivo survival after delivery into target areas. 4, 5 It has been shown that the number of mesenchymal stem cells (MSCs) in the cremaster decreased to 14%
of the initial number 3 days after bolus injection into the ipsilateral common iliac artery in rats. 6 MSCs were initially accumulated in the lungs and did not reach the target sites after intravenous infusion, and many cells disappeared 2 hours after delivery in mice. 7 When the stem cells were injected into the left ventricular myocardium of mice, less than 1% of the delivered cells survived in the target areas 4 days after injection. 4 The mechanisms for the poor survival of transplanted BMSCs have not been fully understood and are very likely multifactorial including inflammation, oxidative stress, mechanical stress and hypoxia. Oxidized low-density lipoproteins (ox-LDLs) are naturally present in serum and an important source for reactive oxygen species (ROS) and oxidative stress. 8, 9 Ox-LDL has been shown to inhibit proliferation and endothelial differentiation of BMSCs, and induce apoptosis of BMSCs with both ROS-dependent and ROS-independent mechanisms. 10, 11 Our previous study showed that ox-LDL impaired the survival of BMSCs in vitro partially through direct cell membrane damage independent of ROS formation.
12
MG53 (also known as TRIM72) is an important membrane-repairing protein that is produced in striated muscle cells and present in circulation. 13 Systemic delivery of MG53 or muscle-specific overexpression of human MG53 gene enhanced membrane repair and improved muscle and heart functions in a hamster model of muscular dystrophies and congestive heart failure. MG53 could protect muscle cells by activating cell survival kinases, such as Akt, extracellular signal-regulated kinases (ERK1/2) and glycogen synthase kinase-3β, and inhibiting proapoptotic protein Bax. 14 Extracellular MG53 protein and recombinant human MG53 protein (rhMG53) could increase membrane repair capacity in isolated muscle or non-muscle cells in a dose-dependent manner. 15, 16 In our previous study, we observed that rhMG53 treatment protected BMSCs against ox-LDL-induced membrane damage and enhanced their survival. However, the protective effect of rhMG53 on BMSCs against ox-LDL was limited with undefined mechanisms.
It is known that ischaemia/reperfusion or hypoxia/oxidative stress leads to down-regulation of MG53 in rodent cardiomyocytes. 17 Hypercholesterolaemia could block sevoflurane-induced cardioprotection against ischaemia-reperfusion injury by alteration of MG53-mediated pathway. 18 Little is known on the metabolism of MG53 in vivo. However, it has been shown that serum MG53 levels in mice with metabolic syndrome induced by a 6-month high-fat diet were significantly reduced. 19 S-nitrosylation of MG53 at C144
(cysteine 144) prevented oxidation-induced degradation of MG53 following oxidative insult, therefore enhancing cardiomyocyte survival. 20 In the present study, we tested the hypothesis that the limited protective effect of MG53 on BMSCs against ox-LDL was due to ox-LDL-induced reduction of MG53. Both in vitro and in vivo experiments were conducted to test the hypothesis. The objectives of the present study were (a) to determine the effect of ox-LDL on MG53 levels both in vitro and in vivo and (b) to define the role of ROS in mediating the effect of ox-LDL-induced reduction of MG53 by blocking ROS production with antioxidant N-acetylcysteine (NAC).
| MATERIAL S AND ME THODS

| Animals
All the animal experiments were performed in accordance with 
| Preparation of LDL and ox-LDL
Both native LDL and ox-LDL were prepared for the experiments as described. 10, 21, 22 Briefly, plasma was obtained from healthy human volunteers for the preparation of native LDL using sodium bromide stepwise density gradient centrifugation. To prepare ox-LDL, native LDL was exposed to copper sulphate (5 μmol/L) at 37°C for 3 hours, followed by the addition of EDTA (final concentration of 0.25 mmol/L) to terminate the reaction. The degree of LDL oxidation was monitored using thiobarbituric acid reactive substances (TBARS) as described. 10, 21, 22 To ensure product quality and reproducibility, the TBARS value for ox-LDL was maintained in the range of 40-50 nmol malondialdehyde/mg protein. There were no detectable TBARS for native LDL.
| Preparation of rhMG53
High-quality (>97% purity) rhMG53 protein was prepared using E.
coli fermentation as described. 16 The efficacy of rhMG53 on membrane protection was determined as EC50 for each preparation to ensure product quality and reproducibility with our established micro-glass bead injury assay as described. 16, 23 The amount of rhMG53 protein for each experiment was determined to achieve its EC50 concentration as established by micro-glass bead injury assay.
| Cell culture
Rat bone marrow multipotent adult progenitor cells (MAPCs) were used as the source of BMSCs that were prepared and characterized in Dr Verfaillie's laboratory in the Stem Cell Institute at the University of Leuven, Leuven, Belgium. Rate MAPCs were stable phenotypically and were positive for Oct-4, Rex-1, c-Kit and Pdgfr-a and negative for Sca-1, CD34, CD45, Sox-2 and Nanog as extensively described previously. 10, 24, 25 The cells were cultured in 60% low glu- Native LDL and saturated LDL were used as the controls. To determine whether rhMG53 could protect the cells, purified rhMG53 
| Western blot analysis for Akt and STAT3 expressions
Rat MAPCs were homogenized and centrifuged at 14 500 g for 10 minutes, and the supernatant was collected. Protein concentration was determined using the bicinchoninic acid assay. The protein samples (20 μg) were loaded into 8% acrylamide SDS gel. The proteins were transferred to 0.45-mm PVDF membranes (Millipore) and then incubated with 5% non-fat milk. After 1 hour, the preparations were incubated with primary antibodies for total Akt (1:3000, Cell Signaling), phospho-Akt (Ser473) (1:2000, Cell Signaling), total STAT3 (1:3000, Cell Signaling), phospho-STAT3 (Tyr705) (1:1000, Cell Signaling) and GAPDH (1:10000, Sant Cruz). Subsequently, the preparations were incubated with HRP-conjugated secondary antibodies. The blots were then incubated with chemiluminescent substrate (Thermo Scientific), and the bands were detected with X-ray film exposure and analysed using ImageJ software.
| FM1-43 dye entry detection
Rat as per manufacturer's instruction.
| Cell apoptosis assay
Rat MAPCs were plated on 6-well plates with a density of 
| Cell cycle assay
Rat MAPCs were plated on 6-well plates with a density of 2000 cells/ cm 2 for cell cycle analysis. After 24 hours of culture, the cells were treated with ox-LDL (5-10 μmol/L) for an additional 24 hours with or without NAC (1 mmol/L) and/or MG53 (50 μg/mL). Each treatment was in triplicate, and three independent experiments were performed. The cells were then prepared for cell cycle analysis using BrdU/7-AAD kit (Biolegend) according to manufacturer's protocol.
| Statistical analysis
The data from all experiments were presented as mean ± SD (standard deviation). Statistical analyses were performed with unpaired Student's t test (two-sided) for two group of data or one-way ANOVA (analysis of variance) (Sigma Stat 2.03; Aspire Software International)
followed by post hoc conservative Tukey's test for three or more groups of data with multiple comparisons to minimize the type I error as appropriate. The difference was considered statistically significant when a two-tailed P value was equal to or less than .05.
| RE SULTS
| NAC significantly enhanced the protective effect of rhMG53 on MAPCs against ox-LDL-induced inhibition
Healthy growth of MAPCs was observed under the standard conditions. In the presence of ox-LDL (from 1 to 5 μg/mL), the number of MAPCs in the culture system was significantly decreased as expected. Treatment with NAC (1 mmol/L) effectively prevented ox-LDL-induced reduction of the cell number (data not shown).
However, when ox-LDL concentration was increased to 10 μg/mL, NAC treatment did not prevent the reduction of cell number that was consistent with our previous observations. 
| NAC effectively prevented ox-LDL-induced reduction of MG53 protein in vitro and in vivo
It is known that the protective effect of MG53 on cell membrane is dose-dependent. 16 To test the hypothesis that NAC enhanced After 2 hours, only 10% of the injected MG53 protein remained in the blood. By 6 hours, the injected protein was completely removed from the blood. Treating the mice with ox-LDL (once a day for 3 days via tail vein) had no significant effect on MG53 clearance from circulation ( Figure 3B ).
| NAC treatment did not prevent ox-LDLinduced membrane damage of MAPCs in vitro
Membrane integrity plays a critical role in cell survival. Figure 4A,B) .
| NAC treatment prevented ox-LDL-induced inhibition of Akt phosphorylation without enhancing the survival of MAPCs against ox-LDL in vitro
Akt-and STAT3-mediated signalling is important to cell survival and proliferation. To determine the potential role of Akt and STAT3 signalling in mediating the effect of ox-LDL on MAPCs, the levels of total and phosphorylated Akt and STAT3 were evaluated in the cells exposed to ox-LDL with and without NAC treatment. As shown in 
| D ISCUSS I ON
In the present study, rat MAPCs were used as the source of BMSCs as
BMSCs are a mixture of heterogeneous cells with very different phenotypes and different capability of differentiating into multiple cell lineages. 28 MAPCs were isolated from bone marrow, clonally purified and well-characterized multipotent cells with differentiation potential into a variety of cell lineages including endothelial cells, smooth muscle cells, neurons, hepatocytes and cardiac myocytes. 24, 25, 29, 30 MAPCs promote angiogenesis and improve cardiac and limb function when injected into the peri-infarct areas in ischaemic mice. Clinical-grade human MAPCs are safe in human patients and effective on controlling human autoimmune disease and allograft rejection. 39, 40, 43, 44 In addition, rat MAPCs are very stable phenotypically.
Thus, using rat MAPCs in the present study has unique advantage with significant translational and clinical values.
We demonstrated that ox-LDL at the concentrations that were compatible with serum ox-LDL levels or less than that in patients with stable coronary artery diseases 12, [45] [46] [47] MG53 can be secreted into circulation and mediates the protective function of MG53 for tissues and organ systems away from striated muscles. 13 Thus, the level of circulating MG53 could be critical for tissue repair and/or regeneration and could be determined by the combined outcome of MG53 expression and secretion, degradation and clearance from circulation. However, the regulatory mechanism for serum MG53 concentration has not been well defined. It has been
shown that mice with metabolic syndrome induced by 6-month highfat diet (HFD) feeding exhibited a significant increase in serum lipid levels and a significant reduction in circulating MG53 level without change in MG53 expression within skeletal and cardiac muscles. 19 In the present study, we also observed that serum MG53 level was significantly decreased in hyperlipidemic LDLR −/− mice ( Figure 2C ).
One of the important components in blood in hyperlipidemic state is ox-LDL which is considered as a critical contributor to the development of cardiovascular diseases associated with hyperlipidemia (like atherosclerosis). 57 In the present study, we demonstrated that treatment of mice with ox-LDL significantly decreased serum MG53 level without change in MG53 clearance from circulation ( Figure 2B and Figure 3B ). In vitro experiments showed that ox-LDL substantially decreased the level of MG53 (Figure 2A ). These data suggested that hyperlipidemia and ox-LDL might be an important determinant for serum MG53 level very likely through enhanced degradation.
MG53 protein has a cysteine residue at position 144 (C144) 20 that can be irreversibly oxidized by anoxia or hydrogen peroxide (H 2 O 2 ) and associated with decreased cell survival. 20 On the other hand, increased S-nitrosylation (SNO) at C144 of MG53 protein would prevent the unfavourable oxidative modification of C144 by H 2 O 2 , and associated with reduced infarct size, and improved myocardial contraction. 20, 58, 59 It is known that excessive amount of ROS is produced in hyperlipidemic states and associated with increased oxidative stress. 60 A significant amount of ROS could be generated from ox-LDL both in vitro and in vivo that could be effectively inhibited with NAC. 12, 60 The data from the present study showed that ox-LDL treatment significantly decreased MG53 levels both in vitro and in vivo that was effectively prevented with antioxidant NAC (Figure 2 ). It is possible that ox-LDL could interact with MG53, leading to irreversible oxidative modification of MG53 and degradation.
Further studies are needed to determine whether ox-LDL could oxidize the C144 residue to form a disulphide bond and MG53 dimerization, leading to the interruption of normal structure and function of MG53. MG53 is also known to have phospholipid-binding activity including binding to phosphatidylserine or phospholipid-containing liposome. 23, 61, 62 It could be possible that ox-LDL-induced reduction of MG53 might result from the binding of MG53 to phospholipids because ox-LDL is composed of phospholipids. However, when MG53 was incubated with native LDL, no reduction of MG53 level was observed ( Figure S1 ). Degradation or clearance of MG53 in circulation was not significantly affected with ox-LDL treatment in mice ( Figure 3B ). These data suggested that binding to phospholipids might not be a dominant mechanism for decreased MG53 levels.
However, further studies are needed to define the interactions between MG53 and phospholipids. Another potential mechanism for decreased MG53 level by ox-LDL could be ox-LDL-induced reduction of MG53 secretion into the circulation that also requires further evaluation.
One of the major challenges to cell therapy with stem cells including BMSCs is the poor in vivo survival after delivery into target tissues. However, the factors that are involved in the in vivo survival of delivered stem cells have not been well defined. Our previous study showed that ox-LDL significantly impaired the survival of MAPCs in vitro partially through direct membrane damage independent of ROS production when ox-LDL was at 10 μg/mL or higher as NAC treatment completely blocked ROS production from ox-LDL and yet failed to protect ox-LDL-induced membrane damage in MAPCs. Treatment with rhMG53 effectively protected
MAPCs against ox-LDL-induced membrane damage, but only partially enhanced their survival. 12 In the present study, we observed In conclusion, the data from the present study suggested that ox-LDL significantly impaired the survival of MAPCs partially through direct membrane damage independent of ROS production in vitro.
NAC treatment synergistically enhanced the protective effect of MG53 on the survival of MAPCs against ox-LDL through attenuation of ox-LDL-induced reduction of MG53.
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